Soliris eculizumab: Phase III data

Top-line data from the double-blind, international Phase III REGAIN trial in 125 refractory generalized myasthenia gravis patients showed that IV Soliris missed the primary endpoint of improving MG-ADL total

Read the full 298 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE